Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F15%3A43909639" target="_blank" >RIV/00216208:11120/15:43909639 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1097/JCP.0000000000000309" target="_blank" >http://dx.doi.org/10.1097/JCP.0000000000000309</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/JCP.0000000000000309" target="_blank" >10.1097/JCP.0000000000000309</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study

Popis výsledku v původním jazyce

The multicenter, observation prospective cohort study adresses the risk associated with exposure to mirtazapine during pregnancy. Pregnancy outcomes after exposure to mirtazapine were compared with 2 matched control groups: to exposure to any selective reuptake inhibitor (SSRI) and no exposure to medication known to be teratogenic or any antidepressant (general control subject). The rate of major birth defects between the mirtazapine and SSRI group did not differ signiificantly, as well as compared to general control. A marginally higher rate of birth defect was, however, observed in the hirtazepine and SSRI compared with the low rate of birth defect in our general control.

Název v anglickém jazyce

Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study

Popis výsledku anglicky

The multicenter, observation prospective cohort study adresses the risk associated with exposure to mirtazapine during pregnancy. Pregnancy outcomes after exposure to mirtazapine were compared with 2 matched control groups: to exposure to any selective reuptake inhibitor (SSRI) and no exposure to medication known to be teratogenic or any antidepressant (general control subject). The rate of major birth defects between the mirtazapine and SSRI group did not differ signiificantly, as well as compared to general control. A marginally higher rate of birth defect was, however, observed in the hirtazepine and SSRI compared with the low rate of birth defect in our general control.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

<a href="/cs/project/LA08034" target="_blank" >LA08034: Členství v European Network of Teratology Information Services (ENTIS)</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Clinical Psychopharmacology

ISSN

0271-0749

e-ISSN

—

Svazek periodika

35

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

250-259

Kód UT WoS článku

000353817400007

EID výsledku v databázi Scopus

—